Literature DB >> 11230837

Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia.

P N Hopkins1, S Stephenson, L L Wu, W A Riley, Y Xin, S C Hunt.   

Abstract

Age at onset of clinically manifested coronary artery disease (CAD) varies widely among patients with familial hypercholesterolemia (FH). A number of factors in addition to high low-density lipoprotein cholesterol (LDL) have been suggested as predictors of risk among patients with FH, but a comprehensive examination of their utility is lacking. We therefore measured plasma lipids, carotid intima-medial thickness, and a variety of coronary risk factors in 262 patients with FH > or = 30 years old (68 of whom had premature CAD). Age (p < 0.0001) and gender were the most important determinants of premature CAD risk, with men having 5.64 times the risk of women (p < 0.0001). In addition, cigarette smoking (odds ratio [OR] 2.71, p = 0.026), smaller LDL as determined by the LDL cholesterol/LDL apolipoprotein B ratio (OR 2.60, p = 0.014), and white blood cell count (p = 0.014) were also statistically significant risk factors. Lipoprotein(a) and the presence of xanthoma were associated with risk only in very early coronary cases. After correction for age, carotid intima-media thickness was not associated with CAD risk. Insulin, fibrinogen, homocysteine, plasma C-reactive protein, and the angiotensin-converting enzyme insertion/deletion polymorphism were unrelated to risk in this cohort. These results provide little justification for extensive investigation of risk factors among patients with FH, at least for the risk factors examined here. Rather, the inherent high LDL cholesterol of these patients should be the focus of preventive efforts. The novel finding of increased risk with smaller LDL may prove useful but needs further confirmation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11230837     DOI: 10.1016/s0002-9149(00)01429-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  21 in total

1.  Early onset of coronary heart disease in a young woman with familial hypercholesterolemia: coronary findings and effect of short term treatment with high dose atorvastatin.

Authors:  Natale Daniele Brunetti; Deodata Montrone; Riccardo Ieva; Antonio Ruggiero; Michele Correale; Luisa De Gennaro; Matteo Di Biase
Journal:  J Thromb Thrombolysis       Date:  2012-02       Impact factor: 2.300

Review 2.  Familial Hypercholesterolaemia Diagnosis and Management.

Authors:  Rodrigo Alonso; Leopoldo Perez de Isla; Ovidio Muñiz-Grijalvo; Jose Luis Diaz-Diaz; Pedro Mata
Journal:  Eur Cardiol       Date:  2018-08

3.  Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.

Authors:  Emil M deGoma; Zahid S Ahmad; Emily C O'Brien; Iris Kindt; Peter Shrader; Connie B Newman; Yashashwi Pokharel; Seth J Baum; Linda C Hemphill; Lisa C Hudgins; Catherine D Ahmed; Samuel S Gidding; Danielle Duffy; William Neal; Katherine Wilemon; Matthew T Roe; Daniel J Rader; Christie M Ballantyne; MacRae F Linton; P Barton Duell; Michael D Shapiro; Patrick M Moriarty; Joshua W Knowles
Journal:  Circ Cardiovasc Genet       Date:  2016-03-24

4.  Premature coronary heart disease and autosomal dominant hypercholesterolemia: Increased risk in women with LDLR mutations.

Authors:  Zahid Ahmad; Xilong Li; Jedrek Wosik; Preethi Mani; Joye Petr; George McLeod; Shatha Murad; Li Song; Beverley Adams-Huet; Abhimanyu Garg
Journal:  J Clin Lipidol       Date:  2015-09-25       Impact factor: 4.766

5.  Familial Hypercholesterolemia.

Authors:  Paul N. Hopkins
Journal:  Curr Treat Options Cardiovasc Med       Date:  2002-04

6.  Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials.

Authors:  Raul D Santos; Frederick J Raal; Alberico L Catapano; Joseph L Witztum; Elisabeth Steinhagen-Thiessen; Sotirios Tsimikas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-01-22       Impact factor: 8.311

7.  Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia.

Authors:  S van Wissen; T J Smilde; M D Trip; Th de Boo; J J P Kastelein; A F H Stalenhoef
Journal:  Heart       Date:  2003-08       Impact factor: 5.994

8.  Hyperlipoproteinaemia(a) is a common cause of autosomal dominant hypercholesterolaemia.

Authors:  E Meriño-Ibarra; J Puzo; E Jarauta; A Cenarro; D Recalde; A L García-Otín; E Ros; E Martorell; X Pintó; M Franco; D Zambón; A Brea; M Pocoví; F Civeira
Journal:  J Inherit Metab Dis       Date:  2007-10-20       Impact factor: 4.982

Review 9.  Hyperlipoproteinemia type 3: the forgotten phenotype.

Authors:  Paul N Hopkins; Eliot A Brinton; M Nazeem Nanjee
Journal:  Curr Atheroscler Rep       Date:  2014-09       Impact factor: 5.113

10.  Altered composition of triglyceride-rich lipoproteins and coronary artery disease in a large case-control study.

Authors:  Paul N Hopkins; M Nazeem Nanjee; Lily L Wu; Michael G McGinty; Eliot A Brinton; Steven C Hunt; Jeffrey L Anderson
Journal:  Atherosclerosis       Date:  2009-05-22       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.